Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis by Yuen, MF et al.
Title
Correlation of liver stiffness and histological features in healthy
persons and in patients with occult hepatitis B, chronic active
hepatitis B, or hepatitis B cirrhosis
Author(s) Fung, J; Lai, CL; Chan, SC; But, D; Seto, WK; Cheng, C; Wong,DKH; Lo, CM; Fan, ST; Yuen, MF
Citation American Journal Of Gastroenterology, 2010, v. 105 n. 5, p. 1116-1122
Issued Date 2010
URL http://hdl.handle.net/10722/76474
Rights Creative Commons: Attribution 3.0 Hong Kong License
   
Correlation of liver stiffness and histological features in healthy persons, and 
patients with occult hepatitis B, chronic active hepatitis B, and hepatitis B cirrhosis 
 
James Fung1, Ching-Lung Lai1, See-Ching Chan2, David But1, Wai-Kay Seto1, Charles 
Cheng1, Danny Ka-Ho Wong1, Chung-Mau Lo2, Sheung-Tat Fan2, Man-Fung Yuen1
 
1. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
Kong SAR 
2. Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong 
Kong SAR 
 
Running title: Liver stiffness in hepatitis B and healthy subjects 
Key words: Liver stiffness, hepatitis b, occult hepatitis b, cirrhosis, chronic hepatitis b 
Word count: 2970 
Reprints address and correspondence: 
Prof Man-Fung Yuen 
Department of Medicine, The University of Hong Kong, Queen Mary Hospital 
Pokfulam Road 
Hong Kong SAR 
Tel: +852 2855 3984 
Fax: +852 2816 2863 
Email: mfyuen@hkucc.hku.hk
   
Abstract 
 
Background: Liver stiffness measurement using transient elastography has become a 
popular tool to assess liver fibrosis.  
Aim: To determine liver stiffness values and histological features in healthy subjects and 
patients with chronic hepatitis B. 
Patients and Methods: A total of 157 persons were included (28 healthy subjects, 18 
occult hepatitis B infection, 102 active chronic hepatitis B, and 9 end-stage hepatitis B 
cirrhosis). Histology and liver stiffness measurements were obtained from all patients. 
Results: The median liver stiffness in healthy subjects, occult hepatitis B, active hepatitis 
B, and end-stage cirrhosis were 4.6, 4.2, 8.7, and 33.8 kPa respectively. In healthy 
subjects and patients with occult hepatitis B infection, no one had significant fibrosis on 
histology and all had liver stiffness <7.2 kPa. In patients with chronic active hepatitis B, 
32 (31%) had liver stiffness >11.0 kPa, but only 4 (12%) had cirrhosis on histology. 
Using liver stiffness to predict cirrhosis in this group had a sensitivity of 100%, 
specificity of 69%, a positive predictive value of 10%, and a negative predictive value of 
100%. All 9 patients with end-stage liver cirrhosis had liver stiffness >11.0 kPa. The 
overall AUROC for diagnosing cirrhosis using a cut-off of 11.3 kPa was 0.89.  
Conclusion: Liver stiffness measurement has an overall good diagnostic accuracy with 
excellent negative predictive value. However, in chronic active hepatitis B with elevated 
ALT levels, the positive predictive value for diagnosing cirrhosis is poor, and further 
studies are needed to optimize the use of transient elastography in this important group. 
   
Background 
In patients with chronic liver diseases, determination of the degree of liver fibrosis and 
the presence of cirrhosis has important implications for prognostic, therapeutic and 
monitoring purposes. Although liver biopsy currently remains the gold standard in the 
assessment of liver fibrosis, it has associated risks of morbidity and less commonly, 
mortality.[1] There has been a rapid increase in the development of non-invasive methods 
to assess liver fibrosis. Measuring liver stiffness using transient elastography has recently 
become available for research and clinical practice to assess liver fibrosis and cirrhosis. 
The majority of the early validating studies have been performed in patients with chronic 
hepatitis C in the Western population. Subsequent validation studies with other liver 
diseases further support its usefulness.[2-5] However, compared to hepatitis C, there is 
still relatively limited data on liver stiffness in chronic hepatitis B.  
 
The rationale for transient elastography is based on the theory that liver stiffness is 
positively correlated with the amount of fibrotic tissue within the liver. In a study of 429 
healthy subjects without known liver diseases, the mean liver stiffness measurement was 
reported to be 5.49 kPa ± 1.59.[6] For patients with chronic liver disease, higher liver 
stiffness measurements are observed with increasing level of fibrosis, with higher liver 
stiffness cut-off values corresponding to increasing stages of fibrosis. In patients with 
cirrhosis, the optimal cut-off values used for patients with cirrhosis can range from 11.0 
to 25.3 kPa, depending on the underlying liver disease.[2, 4, 7-9] 
 
   
It is well established that the cut-off liver stiffness values used for different fibrosis stages 
are dependent on the underlying disease. However, there is increasing evidence to 
suggest that even within the same disease, the optimal cut-off values for different degrees 
of fibrosis may vary with the underlying inflammatory activity, as reflected by higher 
levels of serum alanine aminotransferase (ALT).[10] In patients with chronic hepatitis B 
(CHB), the inflammatory activity and its surrogate marker, ALT level, can fluctuate 
during the course of the disease. Several recent studies have shown that underlying 
inflammatory activity can increase liver stiffness values, causing an overestimation of the 
degree of fibrosis.[11-13]  
 
In the current study, we determined liver stiffness values and histological features in 
subjects with no known liver disease, occult hepatitis B infection, active CHB, and 
hepatitis B-related cirrhosis, and to compare differences between these 4 groups of 
subjects.  
 
Patients and Methods 
The present study recruited a total of 187 subjects from Queen Mary Hospital, University 
of Hong Kong, Hong Kong, between the periods of November 2005 to November 2008. 
There were 4 groups of subjects (28 healthy subjects, 18 occult hepatitis B patients, 121 
active CHB patients, and 20 end-stage cirrhosis patients). The group without known 
underlying liver disease (healthy subjects) was living-related donors recruited from the 
liver transplant program at Queen Mary Hospital. Subjects in this group were negative for 
hepatitis B surface antigen (HBsAg), antibody to hepatitis C virus, significant alcohol 
   
intake history (as defined by an intake of >20g/day), or any other known liver diseases. 
Patients with occult hepatitis B infection were recruited from healthy blood donors who 
were negative for HBsAg, but positive for hepatitis B core antibody (anti-HBc) with 
detectable HBV DNA (method described below). Patients with active CHB were 
recruited from the hepatitis clinic at Queen Mary Hospital. These patients were positive 
for HBsAg for over 6 months, with elevated ALT and HBV DNA levels >20,000 IU/mL. 
The hepatitis B-related cirrhosis group was liver transplant recipients recruited from the 
liver transplant program. Written and verbal consent was obtained for liver biopsy and 
liver stiffness measurements respectively. This study has been approved by the 
Institutional Review Board of the University of Hong Kong. 
 
Liver histology 
All patients included in the current study had liver histology available. Liver biopsy was 
performed on the patient groups with occult hepatitis B and active CHB using a 16G 
Menghini needle after written informed consent. The liver histology was graded using the 
modified hepatic activity index (HAI) score.[14, 15] In the groups with normal subjects 
and HBV-related cirrhosis, histology was obtained at the time of liver transplantation 
from the donor (intra-operative biopsy specimen) and from the recipient (explant 
specimen).  
 
Liver stiffness measurements 
Liver stiffness was measured using transient elastography (Fibroscan, Echosens, Paris, 
France). All patients had transient elastography performed either on the same day or 
   
within one week of obtaining the liver histology. The procedure has been well described 
in earlier studies.[2, 5] Patients who had a success rate of <50%, interquartile range-to-
liver stiffness ratio of >30%, or less than 10 validated measurements, were excluded. 
Liver stiffness scores were expressed as the median value of the validated measurements 
in units of kilopascals (kPa).  
 
Liver biochemistry and viral load 
Complete blood count, coagulation profile, and routine liver biochemistry were 
determined at the time of liver biopsy or surgery. In patients with active CHB, the HBV 
DNA levels were determined using the Cobas Taqman assay, with a lower limit detection 
of 12 IU/mL (Roche Diagnostics, Branchburg, NJ). For detection of occult hepatitis B in 
blood donors, HBV DNA was extracted from 500 μL of serum using the QIAamp DSP 
Virus Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions, 
with a final elution of 26 μL. HBV DNA in the extracts was then quantitatively measured 
by the Artus HBV RG PCR Kit (Qiagen Hamburg GmbH, Hamburg, Germany), using 
the Rotor-Gene 3000 Real-time Multiplexing System (Corbett Research, Mortlake, 
Australia), according to the manufacturer’s instructions. This test has a 95% lower limit 
of quantitation of 3.8 IU/mL of serum and a linear range of detection from 1.1 IU/mL to 
4 × 109 IU/mL of serum. Since the serum HBV DNA levels of these occult HBV subjects 
were very low, in order to eliminate the chance of false positive or negative results, Artus 
HBV test was performed 3 times. Genuine HBV DNA-positive result was defined as 
having ≥2 out of 3 positive HBV DNA signals by 3 independent Artus test runs. 
  
   
Statistical analysis 
All statistical analyses were performed using the SPSS version 14.0 (SPSS Inc, Chicago, 
IL). Continuous variables with skewed distribution were analyzed using Mann Whitney 
test. Related data were analyzed using the Wilcoxon paired test. Continuous variables 
with more than 2 independent samples were analyzed using the Kruskal-Wallis test. 
Correlation between liver stiffness and liver biochemistry and histology score was 
performed using Spearman’s bivariate correlation. Multivariate analysis was performed 
using multiple regressions on variables significant on univariate analysis. The receiver-
operating characteristic  (ROC) curves and area under ROC (AUROC) were calculated. 
The optimal cut-off values were defined as the value giving the highest sensitivity and 
specificity. A p-value of <0.05 was considered statistically significant.  
 
Results 
A total of 187 patients had both liver biopsy and transient elastography performed during 
the study period. Of these, thirty (16%) patients were excluded because of suboptimal 
liver stiffness measurements. Of these suboptimal measurements, eleven patients were 
liver recipients with very small livers and ascites, accounting for the overall higher-than-
expected failure rate of liver stiffness measurements. The remaining 19 patients were 
excluded due to suboptimal measurements secondary to overlying adipose tissue. One 
hundred and fifty-seven patients were included in the final analysis. The demographics 
and laboratory data are summarized in table 1.  
 
Healthy subjects 
   
Twenty-eight liver donors were recruited as healthy subjects, with a median age of 32 
years (range, 18-56) and ALT of 16 U/L (range, 4-51). None of the healthy subjects had 
fibrosis on liver histology. The median liver stiffness was 4.6 kPa (range, 2.0-7.1). 
Twenty-six (93%) subjects had liver stiffness of less than 6.0 kPa. All healthy subjects 
had liver stiffness values of less than 7.2 kPa, the optimal cut-off for F2 as defined in a 
previous study of CHB patients.[7]  
 
Occult hepatitis B 
Eighteen patients with evidence of occult hepatitis B infection were included, with a 
median age of 47 years (range, 20-59) and ALT of 24 U/L (range, 8-48). Fourteen (78%) 
patients had no fibrosis on liver biopsy. The remaining 4 (22%) patients had minimal 
stage 1 fibrosis. The median liver stiffness in patients with occult hepatitis B was 4.2 kPa 
(range, 3.4-6.9), with all patients having liver stiffness values of less than 7.2 kPa. 
 
Active chronic hepatitis B 
One hundred and two patients had active CHB, with a median age of 41 years (range, 18-
63). The median ALT was 89 U/L (range, 46-501). The median liver stiffness was 8.7 
kPa (range, 3.6-44.3).  Thirty-two (31%) patients had liver stiffness value >11.0 kPa, the 
optimal cut-off value for cirrhosis defined in a previous study of CHB patients.[7] Of 
these 32 patients, 12 (38%) had minimal fibrosis (stage 0-1), and a further 16 (50%) 
patients had moderate fibrosis (stage 2-3). The remaining 4 (12%) patients had 
histological cirrhosis with HAI fibrosis stage 5-6. In active CHB, using liver stiffness 
   
measurements to predict cirrhosis had a sensitivity of 100%, specificity of 69%, a 
positive predictive value of 10%, and a negative predictive value of 100%.  
Of these 102 patients with chronic active hepatitis B, 15 patients underwent repeat liver 
biopsies with valid liver stiffness measurements at 12 months after commencing oral 
antiviral therapy with subsequent normalization of ALT. None of these patients had 
cirrhosis at either the first or second biopsy. However, 3 patients had liver stiffness 
measurement of >11.0 kPa indicating cirrhosis before treatment. Of these 3 patients, 2 
had liver stiffness of <11.0 kPa (8.5 and 6.8 kPa) after 1 year of antiviral therapy with 
normalization of ALT. There was a significant decline in liver stiffness after ALT 
normalization compared to the time of active hepatitis (8.6 vs 6.0 kPa, p=0.001) without 
associated significant decline in fibrosis stages.  
 
End-stage CHB cirrhosis 
Nine patients had end-stage liver cirrhosis secondary to CHB requiring liver 
transplantation. The median age was 55 years (range, 51-59), with a median liver 
stiffness of 33.8 kPa (range, 11.9-75.0) and ALT of 91 U/L (range, 16-324). All patients 
had liver stiffness value of >11.0 kPa, the cut-off for cirrhosis in CHB patients.[7] 
 
Comparison of groups 
The demographic and laboratory data of the four different groups are shown in table 2. 
The liver stiffness value of the study population is summarized in figure 1 according to 
their groups. There was no significant difference in median liver stiffness between 
healthy subjects and occult hepatitis B (4.6 vs 4.2 kPa respectively, p=0.796). Patients 
   
with active CHB had a significantly higher median liver stiffness compared with occult 
hepatitis B patients (8.7 vs 4.2 kPa respectively, p<0.001) and healthy subjects (8.7 vs 4.6 
kPa respectively, p<0.001). In patients with minimal (F1) fibrosis in the occult hepatitis 
B and active CHB groups, there was a trend for higher liver stiffness measurement in the 
active CHB group (5.2 vs 7.0 kPa respectively, p=0.066). Patients with end-stage CHB 
cirrhosis had a significantly higher median liver stiffness compared with active CHB 
patients (33.8 vs 8.7 kPa respectively, p<0.001), occult hepatitis B patients (33.8 vs 4.2 
kPa respectively, p<0.001), and healthy subjects (33.8 vs 4.6 kPa respectively, p<0.001).  
 
Relationship between liver stiffness and biological parameters 
The correlation between liver stiffness and biological parameters is shown in table 3. 
There were significant correlations with age, necro-inflammatory activity, histological 
fibrosis, bilirubin, ALP, ALT, AST, GGT, platelets, and INR. After stratification into 
different age groups and levels of ALT and platelets, there were higher liver stiffness 
measurements in patients with higher age groups, higher ALT levels, and lower platelet 
counts (Table 4). After multivariate analysis, histological fibrosis, ALT, AST, GGT, and 
platelets remains significantly correlated with liver stiffness.  
 
Diagnostic performance 
The AUROC, optimal cut-offs, sensitivity and specificity for diagnosing stage 2, 3, and 
≥4 fibrosis for our study population is shown in table 5. The ROC curves for stage 2, 3, 
and ≥4 fibrosis are shown in figure 2. 
 
   
Discussion: 
Transient elastography has been used increasingly as a non-invasive method for assessing 
liver fibrosis. There have been many validating studies performed to date in patients with 
various underlying liver diseases, including chronic hepatitis C, primary biliary disease, 
alcoholic liver disease, fatty liver disease, and CHB.[2, 4, 5, 8, 9] A recent meta-analysis 
on the diagnostic performance of transient elastography has also been published showing 
an AUROC of 0.89 and 0.94 for F3 and F4 respectively.[16] Although earlier studies did 
not show any significant effect of underlying inflammatory activity on liver stiffness 
values, more recent studies have shown that in severe flares of hepatitis, liver stiffness 
may be spuriously elevated.[11-13] 
 
At present, there are less reports regarding liver stiffness on CHB as the technology was 
developed in Europe where hepatitis C is more common. Therefore, most of the earlier 
studies were performed on patients with chronic hepatitis C. In the current study, we 
determined the liver stiffness of healthy subjects and patients at different ends of the 
spectrum of hepatitis B-related diseases ranging from occult infection to end-stage 
cirrhosis. Although the diagnostic accuracy of transient elastography appeared excellent 
with an AUROC of 0.89 for stage 3 and 4 fibrosis, the performance was dependent on the 
underlying disease activity. In both healthy subjects and occult hepatitis B patients (none 
had histological grade of F2, F3 or F4 fibrosis), all subjects had liver stiffness values of 
<7.1 kPa. There were no false positive liver stiffness results indicating advance fibrosis 
or cirrhosis. This suggests that liver stiffness of <7.1 kPa can be safely adopted as 
defining insignificant fibrosis. In patients with end-stage hepatitis B cirrhosis, there were 
   
no false negative results with transient elastography, with all subjects having liver 
stiffness values of >11.0 kPa.  
 
In patients with active CHB, the diagnostic accuracy of transient elastography appeared 
to be dichotomous. It had an excellent negative predictive value of 100% in excluding 
cirrhosis. However, transient elastography had a poor positive predictive value of 10% in 
active CHB; 28 out of 32 patients with liver stiffness >11.0 kPa had no evidence of 
cirrhosis on histology. Therefore, in active CHB, additional tests such as liver biopsy or 
serum markers of fibrosis are required to confirm the presence of severe fibrosis or 
cirrhosis in patients with liver stiffness >11.0 kPa.  
 
Although previous studies have shown that severe necro-inflammatory activity (as 
defined by ALT>1000) can affect liver stiffness, the current study suggests that a much 
lesser degree of inflammation may also increase liver stiffness, and therefore reduce the 
accuracy of transient elastography.[11, 12] These results are also in accordance with a 
previous large population study which have shown that even milder degrees of ALT 
elevation are associated with significantly higher median values of liver stiffness.[17]  
 
In the present study, a cut-off level of liver stiffness of 11.3 kPa for cirrhosis is associated 
with high sensitivity and specificity (93% and 82% respectively) for the overall group 
. This is in accordance with another validating study of CHB patients in which the 
sensitivity and specificity for diagnosing cirrhosis using a cut-off of 11.0 kPa were 93% 
and 87% respectively.[7] The low positive predictive value of 11.0 kPa in the present 
   
study for the group with active hepatitis can be explained by the different population 
studied. The median ALT of the current study was higher than that of the previous study 
(89 vs 54 U/L respectively). In addition, after multivariate analysis, both ALT and AST 
were significantly associated with liver stiffness in addition to histological fibrosis and 
platelet levels, whereas only histological fibrosis and platelet levels were significantly 
associated with liver stiffness in the previous validation study. A recent study on CHB 
patients has also shown that patients with the same fibrosis stage albeit higher ALT levels 
tend to have higher liver stiffness values, and the diagnostic performance of transient 
elastography is reduced.[10] It emphasizes the role of abnormal ALT on liver stiffness 
measurement. 
 
Transient elastography remains one of the most promising non-invasive techniques in 
assessing liver fibrosis. As this technology matures with increasing experience, we are 
now beginning to understand the finer intricacies of measuring liver stiffness. The current 
study shows that liver stiffness measurement is not accurate in diagnosing cirrhosis in 
patients with active hepatitis and elevated ALT using the current cut-off values. 
Unfortunately, these patients are also a group in which clinicians are very interested to 
know whether underlying advance fibrosis or cirrhosis is present, so that the decision to 
start antiviral therapy can be made. To increase the diagnostic accuracy of transient 
elastography, the optimal timing of performing a scan needs to be established, that is, 
whether it should be performed (or repeated) after ALT is normalized. An alternative 
approach would be to adopt different cut-off values depending on the ALT, or to combine 
   
liver stiffness values into a more complex model, including markers of inflammation, to 
improve the diagnostic accuracy.  
 
One limitation of the current study was that even though the study had a wide spectrum 
of disease severity, further useful information can be gained with the availability of 
patients with inactive CHB, and with the inclusion of more patients with well-
compensated cirrhosis. Nevertheless, the current study was able to demonstrate the 
performance of transient elastography in a wide range of disease severity. Furthermore, 
the current study provides histological correlation with liver stiffness for the first time in 
healthy patients and in patients with occult hepatitis B. The median liver stiffness in 
healthy subjects in the current study was similar to the mean level of liver stiffness in an 
earlier study of healthy subjects without histological correlation (4.6 and 5.5 kPa 
respectively).[6] Another limitation of the study is that the body weight and body mass 
index was not measured, which may affect the liver stiffness measurements.  
 
In conclusion, liver stiffness measurement has an overall good diagnostic accuracy, 
particularly with an excellent negative predictive value in patients with CHB. However, 
in patients with active hepatitis and elevated ALT, measuring liver stiffness has a poor 
positive predictive value, and further studies are required to determine both the optimal 
timing for performing transient elastography, and the optimal cut-off values for different 
levels of inflammatory activity.  
   
Table 1. Baseline demographics of study population 
Parameter Value 
Total patients 
Invalid liver stiffness measurements 
Number in final analysis 
Male gender 
Age (years) 
Groups 
   Healthy subjects 
   Occult hepatitis B 
   Active chronic hepatitis B 
   End-stage hepatitis B cirrhosis 
187 
30 (16%) 
157 
101 (64%) 
41 (18-63) 
 
28(18%) 
18 (11%) 
102 (65%) 
9 (6%) 
Continuous variables are shown as median values, with range in brackets.  
   
Table 2. Demographics and laboratory values of normal subjects, occult hepatitis B, 
active chronic hepatitis B, and hepatitis B-related cirrhosis 
 
Parameter Healthy 
Subjects 
N=28 
Occult 
Hepatitis B 
N=18 
Active Chronic 
Hepatitis B 
N=102 
Hepatitis B 
Cirrhosis 
N=9 
Age 
Male sex 
Bilirubin 
ALT 
AST 
Albumin 
Platelets 
INR 
HAI activity 
Fibrosis stage 
F≤2 
F3-4 
F5-6 
Liver stiffness 
32 (18-56) 
17 (61%) 
9 (4-17) 
16 (4-51) 
18 (11-40) 
45 (38-50) 
246 (173-355) 
0.9 (0.8-1.1) 
0 (0-0) 
0 (0-0) 
28 (100%) 
0 (0%) 
0 (0%) 
4.6 (2.0-7.1) 
47 (20-59) 
14 (78%) 
8 (4-13) 
24 (8-48) 
26 (12-40) 
45 (41-49) 
236 (155-365) 
0.9 (0.7-1.0) 
1 (0-4) 
0 (0-1) 
18 (100%) 
0 (0%) 
0(0%) 
4.2 (3.4-6.9) 
41 (18-63) 
63 (62%) 
13 (6-30) 
89 (46-501) 
55 (27-255) 
47 (41-54) 
210 (102-334) 
1.0 (0.9-1.4) 
5 (2-12) 
1 (0-6) 
88 ((86%) 
10 (10%) 
4 (4%) 
8.7 (3.6-44.3) 
55 (51-59) 
7 (78%) 
28 (18-565) 
91 (16-324) 
110 (29-512) 
33 (22-45) 
64 (33-189) 
1.4 (1.0-1.9) 
4 (0-12) 
6 (6-6) 
0 (0%) 
0 (0%) 
9 (100%) 
33.8 (11.9-75) 
Units: age in years, bilirubin in umol/L, ALT in U/L, AST in U/L, albumin in g/L, 
platelets in 109/L, fibrosis stage in HAI, liver stiffness in kPa. Continuous variables are 
   
displayed as median values. HAI=histology activity index, ALT=alanine 
aminotransferase, AST=aspartate aminotransferase, INR=international normalized ratio 
 
 
   
Table 3. Correlation between liver stiffness and demographic and laboratory data 
Parameter Correlation co-efficient P value 
Age 
HAI activity 
HAI fibrosis 
Bilirubin 
ALP 
ALT 
AST 
GGT 
Albumin 
Platelets 
INR 
0.204 
0.626 
0.636 
0.408 
0.342 
0.550 
0.624 
0.397 
0.021 
-0.513 
0.531 
0.010 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.794 
<0.001 
<0.001 
* HAI=histology activity index, ALP=alkaline phosphatase, ALT=alanine 
aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, 
INR=international normalized ratio 
   
Table 4. Liver stiffness stratified by age groups, and levels of ALT and platelets 
Parameter Numbers Liver stiffness (kPa) P value 
Age (years) 
<35 
36-55 
>55 
 
ALT 
<1x ULN 
1-2x ULN 
>2x ULN 
 
Platelets (x109/L) 
<150 
150-250 
>250 
 
61 
74 
22 
 
 
50 
52 
55 
 
 
23 
94 
40 
 
5.6 (2.4-34.3) 
7.3 (2.0-75.0) 
8.7 (3.3-49.6) 
 
 
4.7 (2.0-75.0) 
8.6 (3.4-44.3) 
9.5 (4.5-75.0) 
 
 
16.0 (5.3-75.0) 
6.8 (2.0-34.3) 
5.3 (2.7-20.5) 
0.027 
 
 
 
 
<0.001 
 
 
 
 
<0.001 
* ALT=alanine aminotransferase, ULN=upper limit of normal.
   
Table 5. The AUROC and optimal cut-off values for liver stiffness measurement in 
diagnosing stage 2, 3, and 4 or more fibrosis. 
 
 Fibrosis 
Stage ≥2 
Fibrosis 
Stage ≥3 
Fibrosis 
Stage ≥4 
AUROC 
Cut-off (kPa) 
Sensitivity 
Specificity 
0.87 
9.4 
81% 
82% 
0.89 
9.9 
91% 
80% 
0.89 
11.3 
93% 
82% 
* AUROC=area under the receiver operating characteristic curve, kPa=kilopascals 
   
Figure Legends 
Figure 1. Liver stiffness measurements in healthy subjects, occult hepatitis B, active 
chronic hepatitis B, and end-stage liver hepatitis B cirrhosis 
 
 
 
 
 
 
 
 
 
   
Figure 2. Receiver Operator Characteristic Curve for Liver Stiffness and greater than 
stage 2 fibrosis, stage 3 fibrosis, and cirrhosis 
   
Study Highlights 
1. What is current knowledge 
a. Transient elastography is useful as a non-invasive method for 
assessing liver fibrosis in chronic hepatitis B 
b. Severe hepatitis flares can affect liver stiffness 
2. What is new here 
a. Transient elastography has an excellent negative predictive value for 
cirrhosis in chronic hepatitis B 
b. Moderate inflammatory activity can also affect liver stiffness 
measurements and the accuracy of transient elastography 
c. A cut-off of <7.1 kPa can be used to exclude underlying significant 
fibrosis in chronic hepatitis B 
d. Patients with occult hepatitis B infection have liver stiffness values 
which are similar to healthy subjects 
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